Surmodics’ Drug-Coated Balloon Gets CE Mark

June 9, 2020

Minnesota-based Surmodics has obtained a CE Mark for its SurVeil drug-coated balloon for treatment of peripheral artery disease (PAD).

The balloon features a proprietary drug-excipient formulation that delivers an evenly distributed and durable drug effect.

Surmodics entered into an agreement with Abbott Laboratories in February 2018 that gave Abbott exclusive worldwide commercialization rights for the product.

View today's stories